Simplification and First Validation of a Short Battery of Patient Questionnaires for Clinical Management of HIV-Infected Patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire®

REFERENCES

• Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ ritonavir). Ann Pharmacother 2002;36:1193–1203.
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63:769–802.
   PubMed Web of Science ®Google Scholar
• Voigt E, Wasmuth JC, Vogel M, et al. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results. Infection. 2004;32:82–88.
   PubMed Web of Science ®Google Scholar
• Bader A, Kremer H, Erlich-Trungenberger I, et al. An adherence typology: coping, quality of life, and physical symptoms of people living with HIV/AIDS and their adher-ence to antiretroviral treatment. Med Sci Monit. 2006;12: CR493-CR500.
   Web of Science ®Google Scholar
• Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2: 38–45.
   PubMedGoogle Scholar
• Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV dis-ease. Health PsychoL 2000;19:124–133.
   PubMed Web of Science ®Google Scholar
• Marquis P, Arnould B, Acquadro C, Roberts WM. Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Develop Res. 2006;67:193–201.
   Web of Science ®Google Scholar
• Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10 (Suppl 2): S125–137.
   PubMed Web of Science ®Google Scholar
• Apolone G, De CG, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeco-nomics. 200119: 187–195.
   Google Scholar
• European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Available at: http://www.emea.europa.eu/pdfs/human/ewp/13939104en.pdf. Accessed July 8, 2009.
   Google Scholar
• Spilker B, Molinek FR Jr, Johnston KA, Simpson RL Jr, Tilson HH. Quality of life bibliography and indexes. Med Care. 1990;28:DS1–77.
   PubMedGoogle Scholar
• Deyo RA. The quality of life, research, and care. Ann Intern Med. 1991114: 695–697.
   Google Scholar
• Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. BMJ. 1992;305: 1074–1077.
   PubMed Web of Science ®Google Scholar
• Jia H, Uphold CR, Wu S, Chen GJ, Duncan PW. Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care STDS. 2005;19:395–405.
   PubMed Web of Science ®Google Scholar
• Lorenz KA, Cunningham WE, Spritzer KL, Hays RD. Changes in symptoms and health-related quality of life in a nationally representative sample of adults in treatment for HIV. Qua/ Life Res. 2006;15:951–958.
   PubMed Web of Science ®Google Scholar
• Jia H, Uphold CR, Zheng Y, et al. A further investiga-tion of health-related quality of life over time among men with HIV infection in the HAART era. Qual Life Res. 2007;16:961–968.
   PubMed Web of Science ®Google Scholar
• Carballo E, Cadarso-Suarez C, Carrera I, et al. Assess-ing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res. 2004;13:587–599.
   PubMed Web of Science ®Google Scholar
• Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481–1496.
   PubMed Web of Science ®Google Scholar
• Carrieri P, Raffi F, Lewden C, et al, and the APROCO study group. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3 year follow-up study. Antiviral Ther. 2003;8:37–46.
   PubMed Web of Science ®Google Scholar
• Ammassari A, Murri R, Pezzotti P, et al. Self-reported symp-toms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28: 445–449.
   PubMed Web of Science ®Google Scholar
• Foster JM, van der MT, Caeser M, Hannaford P. The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges. Pharmacoepidemiol Drug Saf. 2008;17:278–296.
   PubMed Web of Science ®Google Scholar
• Tobias CR, Cunningham W, Cabral HD, et al. Living with HIV but without medical care: barriers to engagement. AIDS Patient Care STDS. 2007;21(6):426–434.
   PubMed Web of Science ®Google Scholar
• Hsiung PC, Fang CT, Chang YY, Chen MY, Wang JD. Com-parison of WHOQOL-BREF and SF-36 in patients with HIV infection. Qual Life Res. 2005;14(1):141–150.
   PubMed Web of Science ®Google Scholar
• Mrus JM, Sherman KE, Leonard AC, Sherman SN, Mandell KL, Tsevat J. Health values of patients coinfected with HIV/ hepatitis C: are two viruses worse than one? Med Care. 2006;44(2)1 58–166.
   Web of Science ®Google Scholar
• World Health Organization. World Health Organization Quality of Life-BREF (WHOQOL-BREF). Available at: http://www.who.int/substance_abuse/research_tools/whogolbref/en/. Accessed July 8,2009.
   Google Scholar
• Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786–798.
   PubMed Web of Science ®Google Scholar
• Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Out-comes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481–493.
   PubMed Web of Science ®Google Scholar
• Cella DF, McCain NL, Peterman AH, Mo F, Wolen D. Devel-opment and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHL) quality of life instrument. Qual Life Res. 1996;5:450–463.
   PubMed Web of Science ®Google Scholar
• Peterman AH, Cella D, Mo F, McCain N. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHL) quality of life instrument. Qual Life Res. 1997;6:572–584.
   PubMed Web of Science ®Google Scholar
• Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin EpidemioL 2001;54(Suppl 1):577–90.
   Google Scholar
• Duracinsky M, Cervoni J, Vincent V, et al. Cultural adapta-tion and validation of a lipodystrophy specific quality of life questionnaire. Int Conf AIDS. 2004:7:11–16.
   Google Scholar
• DeMasi RA, Graham NM, Tolson JM, et al. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Adv Ther 200118: 163–173.
   Google Scholar
• Pratt RJ, Robinson N, Loveday HP, et al. Adherence to antiretroviral therapy: appropriate use of self-reporting in clinical practice. HIV Clin Trials. 2001;2:146–159.
   PubMedGoogle Scholar
• Sodergard B, Halvarsson M, Tully MP, et al. Adherence to treatment in Swedish HIV-infected patients. J Clin Pharm Ther 2006;31:605–616.
   PubMed Web of Science ®Google Scholar
• Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: a novel method for mea-suring adherence to antiretroviral therapy. AIDS Care. 2006;18:853–861.
   PubMed Web of Science ®Google Scholar
• Spire B, Carrieri P, Sopha P, et al. Adherence to antiretro-viral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther 2008; 13 (5):697–703.
   PubMed Web of Science ®Google Scholar
• Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 200115: 2441–2444.
   Google Scholar
• Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Mul-tiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100–1102.
   PubMed Web of Science ®Google Scholar
• Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5:74–79.
   PubMed Web of Science ®Google Scholar
• Carrieri P, Cailleton V, Le M, et al. The dynamic of adher-ence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001;28:232–239.
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Organization Quality of Life HIV instrument (WHOQOL-HIV). Users' manual. Scoring and coding for the WHOQOL-HIV instru-ments. Available at: http://www.who.int/mental_health/media/en/613.pdf. Accessed July 8,2009.
   Google Scholar
• Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: the example of health-related-quality of life - a European guidance document for the improved integration of HRQL assess-ment in the drug regulatory process. Drug Inf. 2002;36: 209–238.
   Web of Science ®Google Scholar
• Revicki DA, Osoba D, Fairclough D, et al. Recommenda-tions on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9:887–900.
   PubMed Web of Science ®Google Scholar
• Santanello NC, Baker D, Cappelleri JC, et al. Regulatory issues for health-related quality of life--PhRMA Health Outcomes Committee workshop, 1999. Value Health. 2002;5:14–25.
   PubMedGoogle Scholar
• Scientific Advisory Committee of the Medical Out-comes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res.2002 ;11:193–205.
   PubMed Web of Science ®Google Scholar
• Carrieri MP, Raffi F, Lewden C, et al, APROCO Study Group. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther. 2003;8(6):585–594.
   PubMed Web of Science ®Google Scholar
• Hamon A, Mesbah M. [Internal statistical validation of a quality of life questionnaire]. Rev Epidemiol Sante Publique. 1999;47:571–583.
   PubMed Web of Science ®Google Scholar
• Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull. 1959;56:81–105.
   PubMed Web of Science ®Google Scholar
• Cronbach U. Coefficient alpha and the internal structure of tests. Psychometrika. 195116(3):297–334.
   Google Scholar
• Nunnally J, Bernstein IH. Psychometric Theory. 3rd ed. New York: McGraw-Hill; 1994.
   Google Scholar
• Cohen J. Statistical Powers Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
   Google Scholar